TRI

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on February 21, 2007

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Examining Group 1632 Patent Application Docket No. USF-182XC1 Serial No. 10/655,873

TP Seur P. Kadwig

Glenn Ladwig, Patent Attorney

FEB 2 3 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

xaminer

Louis D. Lieto, Ph.D.

Art Unit

1632

Applicants

Shyam S. Mohapatra, Mukesh Kumar

Serial No.

10/655,873

Filed

September 5, 2003

Conf. No.

6872

For

Genetic Adjuvants for Immunotherapy

MS AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§1.97 AND 1.98

Sir

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, the applicants have not submitted a copy of the published U.S. applications cited on attached Form PTO/SB/08 pursuant to 37 C.F.R. §1.98(a)(2)(ii).

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

02/26/2007 SFELEKE1 00000010 190065 10655873

01 FC:1806

180.00 DA

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,

Glenn P. Ladwig
Patent Attorney

Patent Attorney

Registration No. 46,853

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

P.O. Box 142950

Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (2 pages); copies of some references cited therein



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

control number.

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/655,873 INFORMATION DISCLOSURE Filing Date September 5, 2003 STATEMENT BY APPLICANT First Named Inventor Shyam S. Mohapatra (use as many sheets as necessary) **Art Unit** 1632 **Examiner Name** Louis D. Lieto, Ph.D. of **Attorney Docket Number** Sheet 2 USF-182XC1

U.S. PATENT DOCUMENTS					
Examiner	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
fnitials*		Number - Kind Code ² (if known)			
	U1_	US-2002/0044919 A1	04-18-2002	Yu	All
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-	<u> </u>		
	U	US-			
	U	US-			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	D	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY				
	F1						
	F2						
	F3						
	F4						
.=	F5						
	F6						
	F7					i i	

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2

Sheet

of

2

Application Number 10/655,873 September 5, 2003 **Filing Date** Shyam S. Mohapatra First Named Inventor **Group Art Unit** 1632 Louis D. Lieto, Ph.D. **Examiner Name USF-182XC1 Attorney Docket Number**

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	R1	DOBSON, J. "Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery" Gene Therapy, 2006, 13:283-287.			
	R2	KINSEY, B. et al. "Non-viral gene delivery to the lungs" Current Gene Therapy, 2005, 5:181-194.			
	R3	KUMAR, M.N.V.R. et al. "Nanoparticle-mediated gene delivery: state of the art" Expert Opin. Biol. Ther., 2004, 4(8):1213-1224.			
	R4	POUTON, C. and SEYMOUR, L. "Key issues in non-viral gene delivery" Adv. Drug Deliv. Rev., 2001, 46:187-203.			
	R5	READ, M. et al. "Barriers to gene delivery using synthetic vectors" Adv. in Genetics, 2005, 53:19-46.			
	R				
	R				
	R				
	R				
	R				
	R				
	R R				

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.